There are 2789 resources available
787P - Endotoxicosis and properties of erythrocyte membranes in patients with cervical cancer receiving combination therapy with dendritic cell-based immunotherapy
Presenter: Irina Goroshinskaya
Session: ePoster Display
788P - Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer
Presenter: Michelle McMullen
Session: ePoster Display
789P - PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
Presenter: Min-Hyun Baek
Session: ePoster Display
691P - Effect of NANOGNB mutations on DNA damage response and efficacy of immune checkpoint inhibitors in advanced renal clear cell carcinoma
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract
791P - Multi-omics characterization of molecular features correlated to perineural invasion in cervical cancer
Presenter: Ting Wan
Session: ePoster Display
621P - Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
Presenter: Bertrand Tombal
Session: ePoster Display
622P - Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
Presenter: Bertrand Tombal
Session: ePoster Display
623P - Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
Presenter: Peter Goebell
Session: ePoster Display
624P - Prevalence and clinical impact of PTEN status in patients (pts) with de novo metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Jonathan Thouvenin
Session: ePoster Display
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display